Effect of narrow band UVB phototherapy plus betamethasone ointment versus narrow band UVB phototherapy plus placebo ointment on the treatment of vitiligo

Effect of narrow band UVB phototherapy plus betamethasone ointment versus narrow band UVB phototherapy plus placebo ointment on the treatment of vitiligo: a double blinded randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201402269014N26

Enrollment

Registered

2014-03-09

Start date

2012-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Narrow band UVB phototherapy thrice a week plus betamethasone ointment twice a day for three months. Intervention 2: Narrow band UVB phototherapy thrice a week plus placebo (eucerin) o

Treatment - Drugs

Placebo

Narrow band UVB phototherapy thrice a week plus betamethasone ointment twice a day for three months.

Narrow band UVB phototherapy thrice a week plus placebo (eucerin) ointment twice a day for three months.

Eligibility

Sex/Gender

All

Age

7 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (a) age of 7 years or older; (b) having bilateral symmetrical vitiligo lesions on upper or lower limbs, face, or trunk; (c) the vitiligo is either stable or progressive; (d) at least 10% of the body surface is affected by the disease. Exclusion criteria: (a) being immunodeficient; (b) being spontaneous repigmentation; (c) having any contraindications for phototherapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Repigmentation of the lesion. Timepoint: at the sixth and twelfth weeks. Method of measurement: based on VASI criteria.	—

Secondary

Measure	Time frame
Evaluation of probable superficial burn. Timepoint: weekly before phototherapy. Method of measurement: through clinical observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Azam Dalirad

Farshchian Hospital

a.delirrad@gmail.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026